Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

Pembrolizumab demonstrated durable antitumor activity in patients with previously treated, advanced microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) tumors, including endometrial cancer, in the nonrandomized, open-label, multicohort, phase II KEYNOTE-158 study (NCT02628067)....

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical oncology Vol. 40; no. 7; p. 752
Main Authors:	O'Malley, David M, Bariani, Giovanni Mendonca, Cassier, Philippe A, Marabelle, Aurelien, Hansen, Aaron R, De Jesus Acosta, Ana, Miller, Jr, Wilson H, Safra, Tamar, Italiano, Antoine, Mileshkin, Linda, Xu, Lei, Jin, Fan, Norwood, Kevin, Maio, Michele
Format:	Journal Article
Language:	English
Published:	United States 01.03.2022
Subjects:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - therapeutic use Biomarkers, Tumor - genetics DNA Mismatch Repair Endometrial Neoplasms - drug therapy Endometrial Neoplasms - genetics Endometrial Neoplasms - pathology Female Follow-Up Studies Humans Microsatellite Instability Middle Aged Non-Randomized Controlled Trials as Topic Prognosis Retrospective Studies Survival Rate
ISSN:	1527-7755, 1527-7755
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!